Free Trial
ETR:GXI

Gerresheimer (GXI) Stock Price, News & Analysis

Gerresheimer logo
€51.85 +1.05 (+2.07%)
As of 04/17/2025

About Gerresheimer Stock (ETR:GXI)

Key Stats

Today's Range
€49.56
€51.90
50-Day Range
€50.80
€81.50
52-Week Range
€81.35
€111.20
Volume
309,705 shs
Average Volume
140,925 shs
Market Capitalization
$1.78 billion
P/E Ratio
15.53
Dividend Yield
2.41%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services. It also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, the company offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. It offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.

Receive GXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gerresheimer and its competitors with MarketBeat's FREE daily newsletter.

GXI Stock News Headlines

The Crypto Market is About to Change Lives
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free.
See More Headlines

GXI Stock Analysis - Frequently Asked Questions

Gerresheimer's stock was trading at €71.00 at the beginning of 2025. Since then, GXI shares have decreased by 27.0% and is now trading at €51.85.
View the best growth stocks for 2025 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gerresheimer investors own include Intel (INTC), Abbott Laboratories (ABT), AutoZone (AZO), Bank of America (BAC), Bayer Aktiengesellschaft (BAYN), Danaher (DHR) and Alcoa (AA).

Industry, Sector and Symbol

Stock Exchange
ETR
Sector
Medical
Industry
Medical Instruments & Supplies
Sub-Industry
N/A
Current Symbol
ETR:GXI
CIK
N/A
Fax
N/A
Employees
11,947
Year Founded
N/A

Profitability

Trailing P/E Ratio
15.22
Forward P/E Ratio
N/A
P/E Growth
0.82
Net Income
$113.29 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.99 billion
Cash Flow
€3.42 per share
Price / Cash Flow
14.85
Book Value
€42.22 per share
Price / Book
1.20

Miscellaneous

Free Float
N/A
Market Cap
$1.74 billion
Optionable
Not Optionable
Beta
0.94
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (ETR:GXI) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners